Cited by 764Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Open access

Aschele, Carlo, Cionini, Luca, Lonardi, Sara, Pinto, Carmine, Cordio, Stefano, Rosati, Gerardo, Artale, Salvatore, Tagliagambe, Angiolo, Ambrosini, Giovanni, Rosetti, Paola, Bonetti, Andrea, Negru, Maria Emanuela, Tronconi, Maria Chiara, Luppi, Gabriele, Silvano, Giovanni, Corsi, Domenico Cristiano, Bochicchio, Anna Maria, Chiaulon, Germana, Gallo, Maurizio, Boni, Luca·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.34.4911

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer. Patients and Methods: Seven hundred forty-seven patients with resectable, locally advanced (cT3-4 and/or cN1-2) adenocarcinoma of the mid-low rectum were randomly assigned to receive pelvic radiation (50.4 Gy in 28 daily fractions) and concomitant infused fluorouracil (225 mg/m 2 /d) either alone (arm A, n = 379) or combined with oxaliplatin (60 mg/m 2 weekly × 6; arm B, n = 368). Overall survival is the primary end point. A protocol-planned analysis of response to preoperative treatment is reported here. Results: Grade 3 to 4 adverse events during preoperative treatment were more frequent with oxaliplatin plus fluorouracil and radiation than with radiation and fluorouracil alone (24% v 8% of treated patients; P < .001). In arm B, 83% of the patients treated with oxaliplatin had five or more weekly administrations. Ninety-one percent, compared with 97% in the control arm, received ≥ 45 Gy (P < .001). Ninety-six percent versus 95% of patients underwent surgery with similar rates of abdominoperineal resections (20% v 18%, arm A v arm B). The rate of pathologic complete responses was 16% in both arms (odds ratio = 0.98; 95% CI, 0.66 to 1.44; P = .904). Twenty-six percent versus 29% of patients had pathologically positive lymph nodes (arm A v arm B; P = .447), 46% versus 44% had tumor infiltration beyond the muscularis propria (P = .701), and 7% versus 4% had positive circumferential resection margins (P = .239). Intra-abdominal metastases were found at surgery in 2.9% versus 0.5% of patients (arm A v arm B; P = .014). Conclusion: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.4911

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Pathological features of rectal cancer after preoperative radiochemotherapy
Dworak, O., Keilholz, L., & Hoffmann, A. (1997) · International Journal of Colorectal Disease · doi:10.1007/s003840050072 · Cited by 1,344
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy
Trotti, A., Byhardt, R. W., Stetz, J., Gwede, C. K., Corn, B. W., Fu, K. K., Gunderson, L. L., McCormick, B. L., Morris∫, M., Rich, T. A., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00559-3 · Cited by 805
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radošević-Jelić, L., Daban, A., Bardet, É., Beny, A., Briffaux, A., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.113 · Cited by 594
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
Chau, I., Brown, G. M., Cunningham, D., Tait, D., Wotherspoon, A. C., Norman, A. R., Tebbutt, N. C., Hill, M. E., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 472

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

LH Sobin, CH Wittekind : International Union Against Cancer (UICC) TNM classification of malignant tumours 1997 5th ed New York, NY John Wiley & Sons

Sorted by citations

Items 101–200 of 764

Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost
Appelt, A. L., Vogelius, I. R., Pløen, J., Rafaelsen, S. R., Lindebjerg, J., Havelund, B. M., Bentzen, S. M., & Jakobsen, A. K. M. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.05.023 · Cited by 57
Neo-adjuvant radiotherapy in rectal cancer
Glimelius, B. L. G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8489 · Cited by 59
Rectal cancer: Neoadjuvant chemoradiotherapy
Rödel, C. M., Hofheinz, R., & Fokas, E. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.06.004 · Cited by 59
Rectal cancer: a review.
Fazeli, M. S., & Keramati, M. R. (2015) · PubMed Central · Cited by 57
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204
Landry, J. C., Feng, Y., Cohen, S. J., Staley, C. A., Whittington, R., Sigurdson, E. R., Nimeiri, H. S., Verma, U. N., Prabhu, R. S., & Benson, A. B. (2013) · Cancer · doi:10.1002/cncr.27890 · Cited by 56
Overview of Radiation Therapy for Treating Rectal Cancer
Kye, B., & Cho, H. (2014) · Annals of Coloproctology · doi:10.3393/ac.2014.30.4.165 · Cited by 58
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer
Thomas, F., Motsinger‐Reif, A. A., Hoskins, J. M., Dvorak, A., Roy, S., Alyasiry, A., Myerson, R. J., Fleshman, J. W., Tan, B. R., & McLeod, H. L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.442 · Cited by 54
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: A near pathologic complete response does not translate into good clinical outcome
Swellengrebel, H. A. M., Bosch, S. L., Cats, A., Vincent, A. D., Dewit, L. G. H., Verwaal, V. J., Nagtegaal, I. D., & Marijnen, C. A. M. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.05.010 · Cited by 54
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
Schroeder, C., Gani, C., Lamprecht, U., von Weyhern, C. H., Weinmann, M., Bamberg, M., & Berger, B. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.722263 · Cited by 53
Neoadjuvant treatment for unresectable rectal cancer: An interim analysis of a multicentre randomized study
Bujko, K., Nasierowska-Guttmejer, A. M., Wyrwicz, L. S., Malinowska, M., Kryński, J., Kosakowska, E., Rutkowski, A., Pietrzak, L., Kępka, L., Radziszewski, J., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.03.001 · Cited by 52
Neoadjuvant-intensified treatment for rectal cancer: Time to change?
Musio, D. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i20.3052 · Cited by 51
Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer
Huang, C., Huang, M., Ma, C., Yeh, Y., Tsai, H., Huang, C., Huang, C., & Wang, J. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0790-3 · Cited by 51
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
Salazar, R., Capdevila, J., Laquente, B., Manzano, J. L., Pericay, C., Villacampa, M. M., López, C., Losa, F., Safont, M. J., Gómez, A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1053-z · Cited by 51
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
Gasparini, G., Torino, F., Ueno, T., Cascinu, S., Troiani, T., Ballestrero, A., Berardi, R., Shishido, J., Yoshizawa, A., Mori, Y., et al. (2012) · Angiogenesis · doi:10.1007/s10456-011-9250-0 · Cited by 50
Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study
Borg, C., André, T., Mantion, G., Boudghene, F. P., Mornex, F., Maingon, P., Adenis, A., Azria, D., Piutti, M., Morsli, O., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu377 · Cited by 49
Clinical predictive factors of pathologic complete response in locally advanced rectal cancer
Felice, F. D., Izzo, L., Musio, D., Magnante, A. L., Bulzonetti, N., Pugliese, F., Izzo, P., Cello, P. D., Lucchetti, P., Izzo, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8133 · Cited by 49
Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis
Yang, Y., Cao, L., Li, Z., Zhao, L., Wu, H.-F., Yue, D., Yang, J.-L., Zhou, Z., & Liu, S. (2016) · Oncotarget · doi:10.18632/oncotarget.9995 · Cited by 50
Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy
Hall, M. D., Schultheiss, T. E., Smith, D. D., Fakih, M., Wong, J. Y. C., & Chen, Y. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1235797 · Cited by 50
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Bains, S. J., Abrahamsson, H., Flatmark, K., Dueland, S., Hole, K. H., Seierstad, T., Redalen, K. R., Meltzer, S., & Ree, A. H. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02458-x · Cited by 57
Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan, J., Liu, K., Kaixuan, L., Li, G., & Zhang, Z. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0454-0 · Cited by 48
Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial
Wolff, H. A., Conradi, L., Beißbarth, T., Leha, A., Hohenberger, W., Merkel, S., Fietkau, R., Raab, H.-R., Tschmelitsch, J., Hess, C. F., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.05.009 · Cited by 48
Diffusion-Weighted Magnetic Resonance Application in Response Prediction before, during, and after Neoadjuvant Radiochemotherapy in Primary Rectal Cancer Carcinoma
Musio, D., Felice, F. D., Magnante, A. L., Ciolina, M., Cecco, C. N. D., Rengo, M., Redler, A., Laghi, A., Raffetto, N., & Tombolini, V. (2013) · BioMed Research International · doi:10.1155/2013/740195 · Cited by 48
Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future
Glimelius, B. L. G. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.658974 · Cited by 46
Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer
Ng, S., Colborn, K. L., Cambridge, L., Hajj, C., Yang, J. T., Wu, A. J.-C., & Goodman, K. A. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.09.010 · Cited by 47
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis
Felice, F. D., Benevento, I., Magnante, A. L., Musio, D., Bulzonetti, N., Caiazzo, R., & Tombolini, V. (2017) · BMC Cancer · doi:10.1186/s12885-017-3323-4 · Cited by 47
Oxaliplatin/fluorouracil‐based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta‐analysis of randomized controlled trials
Zhao, L., Liu, R., Zhang, Z., Li, T., Li, F., Liu, H., & Li, G. (2016) · Colorectal Disease · doi:10.1111/codi.13381 · Cited by 47
Predictors for regional lymph node metastasis in T1 rectal cancer: a population-based SEER analysis
Brunner, W., Widmann, B., Marti, L., Tarantino, I., Schmied, B. M., & Warschkow, R. (2016) · Surgical Endoscopy · doi:10.1007/s00464-016-4759-3 · Cited by 44
Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy
Huang, C., Huang, M., Huang, C.-W., Tsai, H., Su, W., Chang, W., Wang, J., & Shi, H.-Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-69345-9 · Cited by 43
Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial
Chakrabarti, D., Rajan, S., Akhtar, N., Qayoom, S., Gupta, S., Verma, M., Srivastava, K., Kumar, V., Bhatt, M. L. B., & Gupta, R. (2021) · British journal of surgery · doi:10.1093/bjs/znab020 · Cited by 44
Treatment of locally advanced rectal cancer: Controversies and questions
Trakarnsanga, A. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i39.5521 · Cited by 41
The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision
Roselló, S., Papaccio, F., Roda, D., Tarazona, N., & Cervantes, A. M. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.01.001 · Cited by 41
Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells
Wang, Y., Yang, L., Zhang, J., Zhou, M., Shen, L., Deng, W., Liang, L., Hu, R., Wang, Y., Yao, Y., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4514 · Cited by 43
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
Dellas, K., Höhler, T., Reese, T., Würschmidt, F., Engel, E., Rödel, C. M., Wagner, W., Richter, M., Arnold, D., & Dunst, J. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-90 · Cited by 40
Smaller tumor size is associated with poor survival in T4b colon cancer
Huang, B., Feng, Y., Mo, S., Cai, S.-J., & Huang, L.-Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6726 · Cited by 39
Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy
Yoo, R. N., & Kim, H. J. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12253 · Cited by 40
Challenges in the neoadjuvant treatment of rectal cancer: Balancing the risk of recurrence and quality of life
Glynne‐Jones, R., Harrison, M., & Hughes, R. (2013) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2013.06.043 · Cited by 40
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
Zhu, J. Y., Gu, W., Lian, P., Sheng, W., Cai, G., Shi, D., Cai, S., & Zhang, Z. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-130 · Cited by 39
Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study.
Jiao, D., Zhang, R., Gong, Z., Liu, F., Chen, Y., Yu, Q., Sun, L. L., Duan, H., Zhu, S., Liu, F., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2015.12.05 · Cited by 53
Total neoadjuvant therapy for rectal cancer
Goodman, K. A. (2018) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2018.01.004 · Cited by 39
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer
Zhang, J., Huang, M., Cai, Y., Wang, L., Xiao, J., Lan, P., Hu, H., Wu, X., Ling, J., Peng, J., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.07.001 · Cited by 39
The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer
Glynne‐Jones, R., & Jones, S. G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00053-x · Cited by 40
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Dueland, S., Ree, A. H., Grøholt, K. K., Sælen, M. G., Folkvord, S., Hole, K. H., Seierstad, T., Larsen, S. G., Giercksky, K. E., Wiig, J. N., et al. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.01.014 · Cited by 37
Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer
Zheng, J., Feng, X., Hu, W., Wang, J., & Li, Y. (2017) · Medicine · doi:10.1097/md.0000000000006487 · Cited by 38
The emerging role of neoadjuvant chemotherapy for rectal cancer.
Boland, P. M., & Fakih, M. (2014) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.060 · Cited by 37
Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single‐institute phase II study
Yu, X., Wang, Q., Xiao, W., Chang, H., Zeng, Z., Lu, Z., Wu, X., Chen, G., Pan, Z. Z., Wan, D.-S., et al. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0294-z · Cited by 37
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Sælen, M. G., Ree, A. H., Kristian, A., Fleten, K. G., Furre, T., Hektoen, H. H., & Flatmark, K. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-165 · Cited by 37
Rectal cancer
Rödel, C. M., Hofheinz, R., & Liersch, T. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328352ea02 · Cited by 36
Organ preservation in rectal cancer – Challenges and future strategies
Gani, C., Bonomo, P., Zwirner, K., Schroeder, C., Menegakis, A., Rödel, C. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2017.02.002 · Cited by 36
Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study
Lupattelli, M., Matrone, F., Gambacorta, M. A., Osti, M. F., Macchia, G., Palazzari, E., Nicosia, L., Navarria, F., Chiloiro, G., Valentini, V., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0870-4 · Cited by 36
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer
Clifford, R. E., Govindarajah, N., Parsons, J. L., Gollins, S., West, N. P., & Vimalachandran, D. (2018) · British journal of surgery · doi:10.1002/bjs.10993 · Cited by 37
Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients
Felice, F. D., Crocetti, D., MAIURI, V., Parisi, M., Marampon, F., Izzo, L., Toma, G. D., Musio, D., & Tombolini, V. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0692-8 · Cited by 36
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years
Zhang, J., Chi, P., Shi, L., Cui, L., Gao, J., Li, W., Wei, H., Cheng, L., Huang, Z., Cai, G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01676 · Cited by 35
Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?
Geva, R., Itzkovich, E., Shamai, S., Shacham‐Shmueli, E., Soyfer, V., Klausner, J. M., & Tulchinsky, H. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1712-5 · Cited by 34
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer
Jung, M., Shin, S. J., Koom, W. S., Jung, I., Keum, K. C., Hur, H., Min, B. S., Baik, S. H., Kim, N. K., Kim, H., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.08.037 · Cited by 33
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Kalanxhi, E., Meltzer, S., Schou, J. V., Larsen, F. O., Dueland, S., Flatmark, K., Jensen, B. V., Hole, K. H., Seierstad, T., Redalen, K. R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0085-y · Cited by 33
MRI‐based EMVI positivity predicts systemic recurrence in rectal cancer patients with a good tumor response to chemoradiotherapy followed by surgery
Cho, M. S., Park, Y. Y., Yoon, J.-H., Yang, S. Y., Baik, S. H., Lee, K. Y., Kim, I. Y., & Kim, N. K. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25064 · Cited by 31
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
Schiffmann, L., Wedermann, N., Gock, M. C., Prall, F., Klautke, G., Fietkau, R., Rau, B., & Klar, E. (2013) · BMC Surgery · doi:10.1186/1471-2482-13-43 · Cited by 32
Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer
Wang, L., Li, Z., Li, Z., Li, Y., Sun, Y., Ji, J., Gu, J. F., & Cai, Y. (2015) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000294 · Cited by 32
Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer
Gao, Y., Zhang, X., An, X., Cai, M., Zeng, Z., Chen, G., Kong, L., Lin, J., Wan, D., Pan, Z.-Z., et al. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-013-0500-5 · Cited by 31
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
Verstraete, M., Debucquoy, A., Dekervel, J., van Pelt, J. F., Verslype, C., Devos, E., Chiritescu, G., Dumon, K., D’Hoore, A. J. L., Gevaert, O., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.93 · Cited by 30
An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy
Huang, C., Huang, M., Tsai, H., Huang, C.-W., Ma, C., Yeh, Y., Juo, S. H., Huang, C., & Wang, J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16656690 · Cited by 31
On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery
Glimelius, B. L. G. (2017) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2016.1274806 · Cited by 31
Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
Fu, X., Fang, Z., Shu, L.-H., Tao, G., Wang, J., Rui, Z., Zhang, Y., & Tian, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16127 · Cited by 31
A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer
Tey, J. C. S., Leong, C. N., Cheong, W. K., Sze, T. G., Yong, W. P., Tham, I. W. K., & Lee, K. M. (2017) · Journal of Cancer · doi:10.7150/jca.21237 · Cited by 32
Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial
Wang, X., Yu, Y., Meng, W., Jiang, D., Deng, X., Wu, B., Zhuang, H., Wang, C., Shen, Y., Yang, L., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.027 · Cited by 31
Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update
Wo, J. Y.-L., Ashman, J. B., Bhadkamkar, N. A., Bradfield, L., Chang, D. T., Hanna, N. N., Hawkins, M., Holtz, M., Kim, E., Kelly, P., et al. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.11.003 · Cited by 30
Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis
Hüttner, F. J., Probst, P., Kalkum, E., Hackbusch, M., Jensen, K., Ulrich, A. B., Debus, J., Jäger, D., & Diener, M. K. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz081 · Cited by 30
Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Meillan, N., Vernerey, D., Lefèvre, J. H., Manceau, G., Svrcek, M., Augustin, J., Fléjou, J., Lascols, O., Simon, J.-M., Cohen, R., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.057 · Cited by 30
Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer
Diefenhardt, M., Ludmir, E. B., Hofheinz, R., Ghadimi, M. B., Minsky, B. D., Rödel, C. M., & Fokas, E. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2394 · Cited by 30
Patient‐derived tumor organoids predict responses to irinotecan‐based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
Lv, T., Shen, L., Xu, X., Yao, Y., Mu, P., Zhang, H., Wan, J., Wang, Y., Guan, R., Li, X., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34302 · Cited by 31
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research?
Hill, E. J., Nicolay, N. H., Middleton, M. R., & Sharma, R. A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.12.007 · Cited by 30
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer
Blaszkowsky, L. S., Ryan, D. P., Szymonifka, J. D., Borger, D. R., Zhu, A. X., Clark, J. W., Kwak, E. L., Mamon, H. J., Allen, J. N., Vasudev, E., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt516 · Cited by 29
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
Derbel, O., Wang, Q., Desseigne, F., Rivoire, M. L., Méeus, P., Peyrat, P., Stella, M., Martel‐Lafay, I., Lemaistre, A., & de la Fouchardière, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-200 · Cited by 29
Adjuvant chemotherapy for rectal cancer: Is it needed?
Milinis, K. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.225 · Cited by 30
Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience
Felice, F. D., Musio, D., Magnante, A. L., Bulzonetti, N., Benevento, I., Caiazzo, R., & Tombolini, V. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.006 · Cited by 28
γ‑H2AX as a potential indicator of radiosensitivity in colorectal cancer cells
Kawashima, S., Kawaguchi, N., Taniguchi, K., Tashiro, K., Komura, K., Tanaka, T., Inomata, Y., Imai, Y., Tanaka, R., Yamamoto, M., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11788 · Cited by 28
Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients
Glimelius, B. L. G., & Osterman, E. (2020) · Cancers · doi:10.3390/cancers12082289 · Cited by 28
The Role of Capecitabine in Locally Advanced Rectal Cancer Treatment
Fernández-Martos, C., Nogué, M., Cejas, P., Moreno, V., Machancoses, A. H., & Feliú, J. (2012) · Drugs · doi:10.2165/11633870-000000000-00000 · Cited by 28
Neoadjuvant Short- or Long-Term Radio(chemo)therapy for Rectal Cancer: How and Who Should Be Treated?
Rödel, C. M., Trojan, J., Bechstein, W. O., & Woeste, G. (2012) · Digestive Diseases · doi:10.1159/000342038 · Cited by 28
Manometric evaluation of anorectal function in patients treated with neoadjuvant chemoradiotherapy and total mesorectal excision for rectal cancer
Nardi, P. D., Testoni, S. G. G., Corsetti, M., Andreoletti, H., Giollo, P., Passaretti, S. M., & Testoni, P. A. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.09.005 · Cited by 28
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial
Golo, D., But-Hadžić, J., Anderluh, F., Brecelj, E., Edhemović, I., Jeromen, A., Omejc, M., Oblak, I., Secerov-Ermenc, A., & Velenik, V. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0028 · Cited by 27
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review
Fornaro, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6081 · Cited by 26
Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Colorectal Cancer
Huang, L., Li, T., Zhang, J., Liu, S., Fu, B., & Liu, W. Y. (2014) · Medicine · doi:10.1097/md.0000000000000231 · Cited by 26
Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer
Dapper, H., Oechsner, M., Münch, S., Borm, K. J., Peeken, J. C., Mayinger, M. C., Combs, S. E., & Habermehl, D. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1120-0 · Cited by 25
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy
Wen, B., Zhang, L., Wang, C., Huang, R., Peng, H.-H., Zhang, T., Dong, J., Xiao, W., Zeng, Z., Liu, M., et al. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0425-5 · Cited by 27
Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?
Stefano, A. D., Moretto, R., Bucci, L., Pepe, S., Romano, F. J., Cella, A., Attademo, L., Rosanova, M., Falco, S. D., Fiore, G., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.05.004 · Cited by 24
Comparison of 5–FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis
Zou, X., Wang, Q.-W., & Zhang, J. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.009 · Cited by 27
Adjuvant chemotherapy in patients with colorectal cancer. Is there a role in the older adult?
Papamichael, D., Hernandez, P. T., Mistry, R. H., Xenophontos, E., & Kakani, C. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.01.002 · Cited by 25
Multidisciplinary Management of Locally Advanced Rectal Cancer—An Evolving Landscape?
Lee, M., Gibbs, P., & Wong, R. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.06.002 · Cited by 25
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
Lawton, C. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.06.019 · Cited by 25
Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II–III resectable rectal cancer: 5-Year survival data of a randomized controlled trial
Kairevičė, L., Latkauskas, T., Tamelis, A., Petrauskas, A., Paužas, H., Žvirblis, T., Jaruševičius, L., Saladžinskas, Ž., Pavalkis, D., & Jančiauskienė, R. (2017) · Medicina · doi:10.1016/j.medici.2017.05.006 · Cited by 25
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman, C. G., McDonough, S. L., Smalley, S. R., Billingsley, K. G., Lenz, H., Beldner, M. A., Hezel, A. F., Velasco, M. R., Guthrie, K. A., Blanke, C. D., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.008 · Cited by 25
Decision tree algorithm in locally advanced rectal cancer: an example of over-interpretation and misuse of a machine learning approach
Felice, F. D., Crocetti, D., Parisi, M., MAIURI, V., Moscarelli, E., Caiazzo, R. J., Bulzonetti, N., Musio, D., & Tombolini, V. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03102-y · Cited by 24
Outcomes of Neoadjuvant Chemotherapy without Radiation for Rectal Cancer
Matsumoto, T., Hasegawa, S., Zaima, M., Inoue, N., & Sakai, Y. (2015) · Digestive Surgery · doi:10.1159/000430469 · Cited by 24
Neoadjuvant treatment for locally advanced rectal cancer: a systematic review
Uehara, K., & Nagino, M. (2015) · Surgery Today · doi:10.1007/s00595-015-1218-z · Cited by 24
Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5‐fluorouracil for locally advanced rectal cancer
Lu, J., Xiao, Y., Qiu, H., Wu, B., Lin, G., Xu, L., Zhang, G.-N., & Hu, K. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23394 · Cited by 24
Advances in radiotherapy and targeted therapies for rectal cancer
Sermeus, A. B. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.1 · Cited by 24
Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers
Valentini, V., Lambin, P., & Myerson, R. J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.12.001 · Cited by 26
Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation
Bensignor, T., Brouquet, A., Dariane, C., Thirot‐Bidault, A., Lazure, T., Julié, C., Nordlinger, B., Penna, C., & Benoist, S. (2014) · Colorectal Disease · doi:10.1111/codi.12879 · Cited by 25

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Rödel, C. M., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R., Ghadimi, M. B., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 736
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
Aschele, C., Pinto, C., Cordio, S., Rosati, G., Tagliagambe, A., Artale, S., Rosetti, P., Lonardi, S., Boni, L., & Cionini, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18s.cra4008 · Cited by 13
Self-citation
Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.
Aschele, C., Lonardi, S., Cionini, L., Pinto, C., Cordio, S. S., Rosati, G., Bianchi, A. S., Tagliagambe, A., Frisinghelli, M., Zagonel, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3521 · Cited by 42
Self-citation
Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma
Djellali, L., Larbaoui, B., Boukerche, A., Ghazi, S. H., Chaiba, I., Meziane, N., Yekrou, D., & Youcef, D. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15108 · Cited by 1
A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer.
Chitapanarux, I., Chitapanarux, T., Tharavichitkul, E., Mayurasakorn, S., Siriwittayakorn, P., Yamada, S., & Lorvidhaya, V. (2011) · PubMed Central · doi:10.2349/biij.7.4.e25 · Cited by 5

See all

Authors: Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., Bonetti, A., Negru, M. E., Tronconi, M. C., Luppi, G., Silvano, G., Corsi, D. C., Bochicchio, A. M., Chiaulon, G., Gallo, M., & Boni, L.
Affiliations: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
ORCID: Aschele, Carlo
Lonardi, Sara
Pinto, Carmine
Rosati, Gerardo
Bonetti, Andrea
Tronconi, Maria Chiara
Luppi, Gabriele
Silvano, Giovanni
Corsi, Domenico Cristiano
Bochicchio, Anna Maria
Boni, Luca
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-07-10
Volume: 29
Issue: 20
Pages: 2773-2780
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.34.4911
OpenAlex: W2123712900
Cited by: 763
References: 29
Citations by year: 2026: 8 · 2025: 23 · 2024: 24 · 2023: 21 · 2022: 37 · 2021: 42 · 2020: 60 · 2019: 60 · 2018: 59 · 2017: 72 · 2016: 61 · 2015: 83 · 2014: 62 · 2013: 64 · 2012: 69
FWCI: 33.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Sanofi
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: locally advanced rectal cancer, neoadjuvant chemoradiotherapy, oxaliplatin, 5-fluorouracil, pelvic radiotherapy, pathological complete response, circumferential resection margin, lymph node metastasis, treatment toxicity, abdominoperineal resection, overall survival
MeSH terms: Oxaliplatin, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Humans, Italy, Male, Middle Aged, Organoplatinum Compounds, Rectal Neoplasms, Survival Analysis, Dose Fractionation, Radiation, Neoadjuvant Therapy, Medication Adherence, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks